FDA approves monthly maintenance dosing for Eisai/Biogen Alzheimer's drug Leqembi, positive.

From Investing.com: 2025-01-26 18:41:06

The FDA approved monthly maintenance dosing for Eisai and Biogen’s Alzheimer’s drug Leqembi, which slows cognitive decline. Patients can switch to monthly dosing after 18 months of biweekly infusions. The drug clears amyloid beta deposits in an hour-long process at infusion centers. Results from modeling simulations predict maintenance dosing benefits.

Eli Lilly’s Kisunla, a rival Alzheimer’s drug, was approved in July for monthly infusion. Treatment stops once brain scans show no amyloid plaques. Both drugs have safety warnings for brain swelling and bleeds, requiring patient monitoring. Eisai collaborates with BioArctic on Leqembi.



Read more at Investing.com: US FDA OKs monthly maintenance dosing for Eisai/Biogen’s Alzheimer’s drug By Reuters